SEC Company Response from X4 Pharmaceuticals, Inc (XFOR) (CIK 0001501697) (XFOR) — Aug 27, 2019
X4 Pharmaceuticals, Inc (XFOR) (CIK 0001501697)
Date: Aug. 27, 2019 · CIK: 0001501697 · Accession: 0001193125-19-230219
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233161
Letter
X4 PHARMACEUTICALS, INC.
955 Massachusetts Avenue, 4th Floor
Cambridge, MA 02139
August 27, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Sonia Bednarowski
Justin Dobbie
RE: X4 Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-233161
Acceleration Request
Requested Date: August 29, 2019
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-233161) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Thursday, August 29, 2019, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Daniel I. Goldberg of Cooley LLP, counsel to the registrant, at (212) 479-6722.
[Signature page follows]
Sincerely,
X4 PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
X4 PHARMACEUTICALS, INC.
955 Massachusetts Avenue, 4th Floor
Cambridge, MA 02139
August 27, 2019
VIA EDGAR
United
States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Sonia Bednarowski
Justin Dobbie
RE:
X4 Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-233161
Acceleration Request
Requested Date:
August 29, 2019
Requested
Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take
appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-233161) (the “Registration
Statement”) to become effective at 4:00 p.m. Eastern Time on Thursday, August 29, 2019, or as soon thereafter as is practicable.
Once
the Registration Statement has been declared effective, please orally confirm that event with Daniel I. Goldberg of Cooley LLP, counsel to the registrant, at (212) 479-6722.
[Signature page follows]
Sincerely,
X4 PHARMACEUTICALS, INC.
By:
/s/ Adam S. Mostafa
Adam S. Mostafa
Chief Financial Officer
cc:
Paula Ragan, Ph.D., Chief Executive Officer, X4 Pharmaceuticals, Inc.
Daniel I. Goldberg, Cooley LLP
Courtney T. Thorne, Cooley LLP